Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant
This article was originally published in The Gray Sheet
Executive Summary
Reference labs developing less costly "homebrew" tests could supplant diagnostic firms as the vehicle for commercializing pharmacogenomic tests, consultant Richard Barker told attendees at the IBC Dx/Rx Summit March 9 in Reston, Va
You may also be interested in...
Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance
NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions
Genomic Patent Exclusivity Tackled By NIH “Best Practices” Draft Guidance
NIH is floating a three-page draft guidance on best practices for the licensing of genomic inventions
Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29